Systems biology of cisplatin resistance: past, present and future

Cites (322)

Items 201–322 of 322

1. Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent
   Siqing Fu, Aung Naing, Caroline Fu · 2012 · Molecular Cancer Therapeutics
2. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy
   Helen H.W. Chen, Jiang Yan, Wen-Chung Chen, Macus Tien Kuo, Yu-Hsuan Lai, Wu Wei Lai, Hsiao‐Sheng Liu, Wu‐Chou Su · 2011 · Lung Cancer
3. Satraplatin: an orally available platinum analog for the treatment of cancer
   Hak Choy · 2006 · Expert Review of Anticancer Therapy
4. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
   Maki Tanioka, Hiroshi Nokihara, Noboru Yamamoto et al. · 2010 · Cancer Chemotherapy and Pharmacology
5. Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques
   M. El-Khateeb, Trevor G. Appleton, Lawrence R. Gahan, Bruce Gordon Charles, Susan J. Berners‐Price, Ann-Maree Bolton · 1999 · Journal of Inorganic Biochemistry
6. Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents
   Liang Zheng, Yan Long, Wen-Bin Tsai et al. · 2012 · Molecular Cancer Therapeutics
7. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes
   D-w Shen, S-I Akiyama, Patricia V. Schoenlein · 1995 · British Journal of Cancer
8. Rationale for development of platinum analogs.
   Burchenal Jh, Kathleen Kalaher, K Dew · 1980 · PubMed
9. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance
   Kazue Yamamoto, Aikou Okamoto, Seiji Isonishi, Kazunori Ochiai, Yasuyuki Ohtake · 2001 · Cancer Letters
10. Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium The GenBank accession numbers for the sequences reported in this paper are AF233610 (S-1-P lyase), AF233612 (PIP5K), AF233611 (P2Y purine receptor 1), AF233613 (CAAX prenyl protease) and AF233614 (unidentified gene).
    Guochun Li, Hannah Alexander, Natalie S. Schneider · 2000 · Microbiology
11. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria
    Michaela Aichler, Mareike Elsner, Natalie Ludyga, Annette Feuchtinger, Verena Zangen, Stefan K. Maier, Benjamin Balluff, Cédrik Schöne, Ludwig Hierber, Herbert Braselmann et al. · 2013 · The Journal of Pathology
12. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA
    Isabelle Gourdier, Laure Crabbé, Karine Andréau, Bernard Pau, Guido Kroemer · 2004 · Oncogene
13. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs
    Bernhard Michalke · 2010 · Journal of Trace Elements in Medicine and Biology
14. Systems biology of kidney diseases
    Cijiang He, Peter Y. Chuang, Avi Ma’ayan, Ravi Iyengar · 2011 · Kidney International
15. Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
    Vitale, Ilio, Galluzzi, Lorenzo, Vivet, Sonia, Nanty, Lisa, Dessen, Philippe, Senovilla, Laura, Olaussen, Ken A., Lazar, Vladimir, Prudhomme, Michelle, Golsteyn, Roy M. et al. · 2007 · PLoS ONE
16. Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)
    Qi Wang, Meizuo Zhong, Wei Liu, Jianhuang Li, Jin Huang, LE ZHENG · 2011 · Experimental Lung Research
17. Cytoplasmic initiation of cisplatin cytotoxicity
    Fang Yu, Judit K. Megyesi, Peter M. Price · 2008 · American Journal of Physiology-Renal Physiology
18. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.
    Angiolo Gadducci, Stefania Cosio, S Muraca, Andrea Riccardo Genazzani · 2002 · PubMed
19. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid
    Hidemi Rikiishi, Fumiaki Shinohara, Tomonori Sato, Yoshitaro Sato, M. Suzuki, Seishi Echigo · 2007 · International Journal of Oncology
20. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
    Judith Michels, Ilio Vitale, Laura Senovilla, David Pierre Enot, Pauline Garcia, Delphine Lissa, Ken André Olaussen, Catherine Brenner, Jean‐Charles Soria, Maria Castedo et al. · 2013 · Cell Cycle
21. Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell
    Wei Yu, Chengmeng Jin, Xiaoyan Lou, Xu Han, Lisha Li, Yinghua He, Hongyu Zhang, Kelong Ma, Jingde Zhu, Li‐Hua Cheng et al. · 2011 · PLoS ONE
22. REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy
    Huibo Wang, Shuyu Zhang, Shuai Wang, Juan Lü, Wenting Wu, Lin Weng, Dan Chen, Yu Zhang, Zhipeng Lu, H. J. Yang et al. · 2009 · Neuro-Oncology
23. Let-7b expression determines response to chemotherapy through the regulation of Cyclin D1 in Glioblastoma
    Yong Gang Guo, Kuipo Yan, Jiasheng Fang · 2013 · Journal of Experimental & Clinical Cancer Research
24. Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen
    Wataru Ichikawa, Takehiro Takahashi, K. Suto, Yasutsuna Sasaki, Renzo Hirayama · 2006 · Clinical Cancer Research
25. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73
    Su Wei Wong, Kai Hung Tiong, Weng Yip Kong, Yuen Chee Yue, Choon Hooi Chua, Jae Ying Lim, Chai Yuin Lee, Sean I. Quah, Cindy Fow, Cyril Chung et al. · 2010 · Breast Cancer Research and Treatment
26. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma
    Takeshi Aida, Yuji Takebayashi, Takao Shimizu, Chikako Okamura, Masashi Higasimoto, Atsuko Kanzaki, Kentaro Nakayama, Kunihiko Terada, Toshihiro Sugiyama, Kohji Miyazaki et al. · 2005 · Gynecologic Oncology
27. Ovarian cancer: new clinical approaches
    Robert F. Ozols · 1991 · Cancer Treatment Reviews
28. Proteomic Analysis Identified DJ-1 as a Cisplatin Resistant Marker in Non-Small Cell Lung Cancer
    Huazong Zeng, Yi-Qing Qu, Wenjun Zhang · 2011 · International Journal of Molecular Sciences
29. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin
    Céline F. Jacquemont, Julian A. Simon, Alan D. D’Andrea, Toshiyasu Taniguchi · 2012 · Molecular Cancer
30. Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells.
    T Murata, Hiroshige Hibasami, S Maekawa · 1990 · PubMed
31. RhoJ Regulates Melanoma Chemoresistance by Suppressing Pathways That Sense DNA Damage
    Hsiang Ho, Jayavani Aruri, Rubina Kapadia, Hootan Mehr, Michael A. White, Anand K. Ganesan · 2012 · Cancer Research
32. Survivin as a predictor of cis‐diamminedichloroplatinum sensitivity in gastric cancer patients
    Masashi Nakamura, Naoki Tsuji, Koichi Asanuma, Daisuke Kobayashi, Atsuhito Yagihashi, Koichi Hirata, Toshihiko Torigoe, Noriyuki Sato, Naoki Watanabe · 2004 · Cancer Science
33. Cross-resistance to UV radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified DNA.
    C C Chao, Shuxin Huang, Hongbiao Huang · 1991 · Molecular and Cellular Biology
34. Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs
    Satoshi Mizutani, Yasuyuki Miyato, Yujiro Shidara · 2009 · Cancer Science
35. ATP11B mediates platinum resistance in ovarian cancer
    Myrthala Moreno‐Smith, Jyotsna B. Halder, Paul S. Meltzer, Tamas A. Gonda, Lingegowda Selanere Mangala, Rajesha Rupaimoole, Chunhua Lü, Archana Sidalaghatta Nagaraja, Kshipra M. Gharpure, Yu Kang et al. · 2013 · Journal of Clinical Investigation
36. Identification of Cisplatin-Binding Proteins Using Agarose Conjugates of Platinum Compounds
    Takatoshi Karasawa, Martha Sibrian‐Vazquez, Robert M. Strongin, Peter S. Steyger · 2013 · PLoS ONE
37. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma
    Joyce N. Barlin, Petar Jelinic, Narciso Olvera · 2012 · Gynecologic Oncology
38. Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study
    Dongxin Liu, Steven J O'Day, Dongyun Yang, Peter D. Boasberg, Robert Milford, Tim S. Kristedja, Susan G. Groshen, Jeffrey S. Weber · 2005 · Clinical Cancer Research
39. Heat Shock Protein 27 Protects L929 Cells from Cisplatin-Induced Apoptosis by Enhancing Akt Activation and Abating Suppression of Thioredoxin Reductase Activity
    Yong Zhang, Xun Shen · 2007 · Clinical Cancer Research
40. Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy
    Lingmin Hu, Chen Hsuan Wu, Xueying Zhao et al. · 2012 · Clinical Cancer Research
41. ATP11B mediates platinum resistance in ovarian cancer
    Myrthala Moreno‐Smith, Jyotsna B. Halder, Paul S. Meltzer, Tamas A. Gonda, Lingegowda Selanere Mangala, Rajesha Rupaimoole, Chunhua Lü, Archana Sidalaghatta Nagaraja, Kshipra M. Gharpure, Yu Kang et al. · 2018 · Journal of Clinical Investigation
42. Genomic Screening in Vivo Reveals the Role Played by Vacuolar H+ ATPase and Cytosolic Acidification in Sensitivity to DNA-Damaging Agents Such as Cisplatin
    Chunyan Liao, Bin Hu, Matthew J Arno · 2006 · Molecular Pharmacology
43. Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer
    Nicole P. Chappell, Pang-ning Teng, Brian L. Hood, Guisong Wang, Kathleen M. Darcy, Chad A. Hamilton, George Larry Maxwell, Thomas P. Conrads · 2012 · Journal of Proteome Research
44. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
    Julia Mendoza‐Pérez, Jorge García Martínez, Casandra Hernández Hernández, Delia Pérez‐Montiel, C Castro, Eunice Fabián-Morales, Miguel Santibáñez-Andrade, Rodrigo González‐Barrios, José Díaz‐Chávez, Marco A. Andonegui et al. · 2013 · British Journal of Cancer
45. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations
    Heather E. Wheeler, Eric R. Gamazon, Amy L. Stark, Peter H. O’Donnell, Lidija K. Gorsic, R. Stephanie Huang, Nancy Jean Cox, M. Eileen Dolan · 2011 · The Pharmacogenomics Journal
46. Microarrays
    Norman H. Lee, Alexander I. Saeed · 2007 · Methods in molecular biology
47. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells
    Yi-Yong Qiu, Bernard L. Mirkin, Rama S. Dwivedi · 2005 · Cancer Detection and Prevention
48. Reactive oxygen species‐dependent EndoG release mediates cisplatin‐induced caspase‐independent apoptosis in human head and neck squamous carcinoma cells
    Jong Soo Kim, Ji Hae Lee, Won Wook Jeong et al. · 2007 · International Journal of Cancer
49. Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention
    Michelle A.T. Hildebrandt, Scott Michael Lippman, Carol Jean Etzel, Edward Kim, J. Jack Lee, Fadlo Raja Khuri, Margaret R. Spitz, Reuben Lotan, Waun Ki Hong, Xifeng Wu · 2012 · Clinical Cancer Research
50. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients
    Baohui Han, Ge Gao, Wenting Wu, Zhiqiang Gao, Xueying Zhao, Ling Li, Rong Qiao, Hongyan Chen, Qingyi Wei, Jinchang Wu et al. · 2010 · Lung Cancer
51. MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy
    Michael A. Ko, Guan Zehong, Carl Virtanen · 2012 · The Annals of Thoracic Surgery
52. The Translesion Polymerase Rev3L in the Tolerance of Alkylating Anticancer Drugs
    Wynand Paul Roos, Anastasia Tsaalbi‐Shtylik, Roman Tsaryk, Fatma Güvercin, Niels de Wind, Bernd Kaina · 2009 · Molecular Pharmacology
53. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents
    Anastasia R. Goloudina, Kan Tanoue, Arlette Hammann, Eric Fourmaux, Xavier Le Guezennec, Dmitry V. Bulavin, Sharlyn J. Mazur, Ettore Appella, Carmen Garrido, Oleg N. Demidov · 2011 · Proceedings of the National Academy of Sciences
54. Oncology studies using siRNA libraries: the dawn of RNAi-based genomics
    Christoph Sachse, Christophe J. Echeverri · 2004 · Oncogene
55. Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin
    Luiz Claudio Godoy, Chase C.T. Anderson, Rajdeep Chowdhury, Laura J. Trudel, Gerald N. Wogan · 2012 · Proceedings of the National Academy of Sciences
56. Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
    Ji‐Youn Han, Eun Kyung Hong, Byung Gil Choi, Jin No Park, Ki Won Kim, Jin‐Hyoung Kang, Jong‐Youl Jin, Suk Young Park, Young Seon Hong, Kyung Shik Lee · 2003 · Medical Oncology
57. Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy
    Min Kyoung Kim, Kyung-Ja Cho, Gui Young Kwon, Seung-Il Park, Yong‐Hee Kim, Jong Hoon Kim, Ho-Young Song, Ji Hoon Shin, Hwoon‐Yong Jung, Gin Hyug Lee et al. · 2008 · Clinical Cancer Research
58. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines
    Lijuan Zhuo, Jingfeng Liu, Bin Wang · 2012 · Oncology Reports
59. A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110γ Isoform in Medulloblastoma Cell Proliferation and Chemoresistance
    Ana Guerreiro Stücklin, Sarah Fattet, Dorota W. Kulesza et al. · 2011 · Molecular Cancer Research
60. Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance
    Ding‐Wu Shen, Jichun Ma, Mitsunori Okabe, Guofeng Zhang, Di Xia, Michael M. Gottesman · 2010 · Journal of Cellular Physiology
61. The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis
    Ida Eriksson, Maria Joosten, Karin B. Roberg, Karin M. Öllinger · 2012 · Experimental Cell Research
62. miR-135a/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1
    Li Qun Zhou, Tianzhu Qiu, Jing Xu · 2013 · Pathology & Oncology Research
63. Loss-of-function alleles ofP2RX7andTLR4fail to affect the response to chemotherapy in non-small cell lung cancer
    Erika Vacchelli, Lorenzo Galluzzi, Vanessa Rousseau, Alice Rigoni, Antoine Tesnière, Nicolas Delahaye, Frédéric Schlemmer, Laurie Menger, Abdul Qader Sukkurwala, Sandy Adjemian et al. · 2012 · OncoImmunology
64. Frameshifts and deletions during in vitro translesion synthesis past Pt–DNA adducts by DNA polymerases β and η
    Ekaterina Bassett, Alexandra Vaisman, Kristen Tropea Leeman, Chad M. McCall, Chikahide Masutani, Fumio Hanaoka, Stephen G. Chaney · 2002 · DNA repair
65. Accuracy of Multiplexed Illumina Platform-Based Single-Nucleotide Polymorphism Genotyping Compared between Genomic and Whole Genome Amplified DNA Collected from Multiple Sources
    Randi A. Paynter, Danica R. Skibola, Christine F. Skibola, Patricia A. Buffler, Joseph Leo Wiemels, Martyn T. Smith · 2006 · Cancer Epidemiology Biomarkers & Prevention
66. PGC-1β mediates adaptive chemoresistance associated with mitochondrial DNA mutations
    Zhi Yao, Aleck W.E. Jones, Elisa Fassone, Mary G. Sweeney, Magdalena Lebiedzińska, Jan M. Suski, Mariusz Roman Wieckowski, Nicolas Tajeddine, Iain Parry Hargreaves, Takehiro Yasukawa et al. · 2012 · Oncogene
67. X-ray and cis-diamminedichloroplatinum(II) cross-resistance in human tumor cell lines.
    J L Schwartz, Jacob Rotmensch, M A Beckett · 1988 · PubMed
68. Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer
    Masahide Ikeguchi, Nobuaki Kaibara · 2001 · International Journal of Molecular Medicine
69. Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil
    SASADA, SHINSUKE, MIYATA, YOSHIHIRO, TSUTANI, YASUHIRO, TSUYAMA, NAOHIRO, MASUJIMA, TSUTOMU, HIHARA, JUN, OKADA, MORIHITO · 2013 · Oncology Reports
70. Quantitative Proteomic and Interaction Network Analysis of Cisplatin Resistance in HeLa Cells
    Juan D. Chavez, Michael R. Hoopmann, Chad R. Weisbrod, Kohji Takara, James E. Bruce · 2011 · PLoS ONE
71. A Systematic Analysis on DNA Methylation and the Expression of Both mRNA and microRNA in Bladder Cancer
    Jialou Zhu, Zhimao Jiang, Fei Gao, Xueda Hu, Liang Zhou, Jiahao Chen, Huijuan Luo, Jihua Sun, Song Wu, Yonghua Han et al. · 2011 · PLoS ONE
72. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: Molecular mechanisms unveiled by gene expression profiling
    Martin Koch, Michaela L. Krieger, Daniel Philipp Stölting, Norbert Brenner, Manfred Beier, Ulrich Jaehde, Michael Wiese, Hans‐Dieter Royer, Gerd Bendas · 2013 · Biochemical Pharmacology
73. Mcl-1, Vascular Endothelial Growth Factor-R2, and 14-3-3σ Expression Might Predict Primary Response against Radiotherapy and Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck
    Boban M. Erović, Martina Pelzmann, Matthäus Ch. Grasl, Pammer Johannes, Gabriela Verena Kornek, Werner Brannath, Edgar Selzer, Dietmar Thurnher · 2005 · Clinical Cancer Research
74. Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents
    Ossama Sharaf El Dein, Cindy Gallerne, Catherine Brenner · 2012 · Biochemical Pharmacology
75. RAB8 Enhances TMEM205-Mediated Cisplatin Resistance
    Ding‐Wu Shen, Michael M. Gottesman · 2011 · Pharmaceutical Research
76. An integrative approach to identify YB‐1‐interacting proteins required for cisplatin resistance in MCF7 and MDA‐MB‐231 breast cancer cells
    Chantal Garand, David R.P. Guay, Chris Sereduk · 2011 · Cancer Science
77. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
    Tatsuya Miyazaki, Hiroyuki Kato, Ahmad Faried, Makoto Sohda, Masanobu Nakajima, Yasuyuki Fukai, Norihiro Masuda, Ryokuhei Manda, Minoru Fukuchi, Hitoshi Ojima et al. · 2005 · PubMed
78. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo
    Stella Okouoyo, Kerstin Herzer, Esat Ucur · 2003 · International Journal of Cancer
79. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma
    Tilahun Jiffar, Taner Yılmaz, J Lee · 2011 · Oncogene
80. Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275
    Annette Bangert, Sabine Häcker, Silvia Cristofanon, Klaus‐Michael Debatin, Simone Fulda · 2011 · Anti-Cancer Drugs
81. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer
    Jian Cheng, HA Min-wen, Yadi Wang · 2011 · Journal of Cancer Research and Clinical Oncology
82. Independent transcriptional reprogramming and apoptosis induction by cisplatin
    Lorenzo Galluzzi, Ilio Vitale, Laura Senovilla, Tobias Eisenberg, Didac Carmona‐Gutiérrez, Erika Vacchelli, Thomas Robert, Hugues Ripoche, Nora Jägemann, Caroline Paccard et al. · 2012 · Cell Cycle
83. p53 and HER2/neu Expression in Relation to Chemotherapy Response in Patients with Non-Small Cell Lung Cancer
    Justyna Fijołek, Elżbieta Wiatr, Ewa Rowinska-Zakrzewska, Dorota Giedronowicz, Renata Langfort, Mariusz Chabowski, Tadeusz Maria Orlowski, Krzysztof Roszkowski · 2006 · The International Journal of Biological Markers
84. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Peter L. J. Naredi, Dennis D. Heath, Robert E. Enns · 1994 · PubMed
85. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study.
    Bożenna Karczmarek-Borowska, Agata Anna Filip, J Wojcierowski, Agata Smoleń, Iwona Pilecka, Andrzej Jabłonka · 2005 · PubMed
86. Cisplatin treatment leads to changes in nuclear protein and microRNA expression
    Guanglin Zhang, Li Sun, Xianghong Lu, Zhanghui Chen, Penelope J. Duerksen-Hughes, Hu Hu, Xinqiang Zhu, Jun Yang · 2012 · Mutation Research/Genetic Toxicology and Environmental Mutagenesis
87. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin
    Lorenzo Galluzzi, Sabrina Marsili, Ilio Vitale, Laura Senovilla, Judith Michels, Pauline Garcia, Erika Vacchelli, Étienne Chatelut, Maria Castedo, Guido Kroemer · 2013 · Cell Cycle
88. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients
    Dianke Yu, Juan Shi, Tong Sun et al. · 2012 · Tumor Biology
89. Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non–Small Cell Lung Cancer Treated with Chemotherapy
    Yafei Li, Zhifu Sun, Julie M. Cunningham et al. · 2011 · Clinical Cancer Research
90. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Motofumi Yoshida, Abdul R. Khokhar, Zahid Hussain Siddik · 1994 · PubMed
91. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts
    Mark A Jones, J Siracký, Lloyd R. Kèlland, Kenneth R. Harrap · 1993 · British Journal of Cancer
92. A metabonomic approach to chemosensitivity prediction of cisplatin plus 5‐fluorouracil in a human xenograft model of gastric cancer
    Wang, Xi, Yan, Shi‐Kai, Dai, Wei‐Xing, Liu, Xin‐Ru, Zhang, Wei‐Dong, Wang, Jie‐Jun · 2010 · International Journal of Cancer
93. Overexpression of IL-7 enhances cisplatin resistance in glioma
    Lei Cui, Jun Fu, Jesse Chung‐Sean Pang · 2012 · Cancer Biology & Therapy
94. Genome-Wide Local Ancestry Approach Identifies Genes and Variants Associated with Chemotherapeutic Susceptibility in African Americans
    Heather E. Wheeler, Lidija K. Gorsic, Marleen M. Welsh, Amy L. Stark, Eric R. Gamazon, Nancy Jean Cox, M. Eileen Dolan · 2011 · PLoS ONE
95. Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells
    Vivekananda Shetty, Zacharie Nickens, James S Testa, Julie Hafner, Gomathinayagam Sinnathamby, Ramila Philip · 2012 · Journal of Proteomics
96. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance
    Fabiana Salm, Paulina Ćwiek, A Ghosal et al. · 2012 · Oncogene
97. Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer
    Mingyong Han, Jianjian Dai, Ying Zhang · 2012 · Oncology Reports
98. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin
    Hye Sook Chon, Douglas C. Marchion, Yin Xiong et al. · 2011 · Gynecologic Oncology
99. Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin
    Kazuto Nishio, Yasuro Sugimoto, Kei Nakagawa · 1990 · British Journal of Cancer
100. Human DNA polymerase eta inserting dCMPNPP opposite CG template (GG0a)
     Yongyun Zhao, Christian Biertümpfel, Mark Gregory, Yue Hua, Fumio Hanaoka, Wenhui Yang · 2012 · Worldwide Protein Data Bank
101. Association Between CASP8 and CASP10 Polymorphisms and Toxicity Outcomes With Platinum-Based Chemotherapy in Chinese Patients With Non-Small Cell Lung Cancer
     Ji Qian, Hui‐Qi Qu, Lixin Yang, Ming Yin, Qiming Wang, Shaohua Gu, Qihan Wu, Xueying Zhao, Wenting Wu, Junjie Wu et al. · 2012 · The Oncologist
102. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients
     Shu-Peng Ho · 2011 · Oncology Reports
103. Platinum Anticancer Drugs
     James C. Dabrowiak · 2009
104. Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast
     Laura Gatti, Kwang‐Lae Hoe, Jacqueline Hayles, Sabina Carla Righetti, Nives Carenini, Laura Dal Bo, Dong U Kim, Han O Park, Paola Perego · 2011 · BMC Genomics
105. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
     Bridget T. Hill, Sharon A. Shellard, Louise K. Hosking · 1992 · PubMed
106. Prognostic value of LIPC in non-small cell lung carcinoma
     Lorenzo Galluzzi, Aïcha Goubar, Ken André Olaussen, Ilio Vitale, Laura Senovilla, Judith Michels, Angélique Robin, Nicolas Dorvault, Benjamin Besse, Pierre Validire et al. · 2013 · Cell Cycle
107. Ras inhibition amplifies cisplatin sensitivity of human glioblastoma
     Samantha Messina, Carlo Leonetti, Giorgia De Gregorio · 2004 · Biochemical and Biophysical Research Communications
108. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: A proteomic analysis
     Radovan Vasko, Gerhard Anton Mueller, Ann-Kristin von Jaschke · 2011 · European Journal of Pharmacology
109. High-Throughput Screening Assay for Identification of Small Molecule Inhibitors of Aurora2/STK15 Kinase
     Chongbo Sun, Yvette M. Newbatt, Leon Douglas · 2004 · SLAS DISCOVERY
110. Ovarian cancer chemotherapy: carboplatin as standard
     Martin H.N. Tattersall · 2002 · The Lancet
111. Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase
     Rawad F. Hodeify, Judit K. Megyesi, Adel Tarcsafalvi · 2010 · American Journal of Physiology-Renal Physiology
112. Mechanism of cisplatin resistance in human urothelial carcinoma cells
     Huimin Yu, Tsing-Cheng Wang · 2012 · Food and Chemical Toxicology
113. Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
     Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, David Simon Ziegler · 2012 · Molecular Cancer Therapeutics
114. A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin
     Ken André Olaussen · 2009 · Cancer Biology & Therapy
115. Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy
     Weiqing Huang, Xuanfeng Ding, B. LI · 2012 · Neoplasma
116. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line
     Tanzawa · 1994 · Oncology Reports
117. A Head and Neck Cancer Tumor Response-Specific Gene Signature for Cisplatin, 5-Fluorouracil Induction Chemotherapy Fails with Added Taxanes
     Tomkiewicz, Céline, Hans, Stéphane, Mucchielli, Marie Hélène, Agier, Nicolas, Delacroix, Hervé, Marisa, Laetitia, Brasnu, Daniel, Aggerbeck, Lawrence P., Badoual, Cécile, Barouki, Robert et al. · 2012 · PLoS ONE
118. α6 integrin subunit mediates laminin enhancement of cisplatin-induced apoptosis in testicular tumor germ cells
     Maoulana Andjilani, Jean‐Pierre Droz, Mohamed Benahmed, Éric Tabone · 2005 · International Journal of Cancer
119. Association of CASP7 Polymorphisms and Survival of Patients With Non-small Cell Lung Cancer With Platinum-Based Chemotherapy Treatment
     Ji Qian, Shaohua Gu, Qihan Wu et al. · 2012 · CHEST Journal
120. A new high resolution screening method for study of phenotype stress responses of Saccharomyces cerevisae mutants
     Håvard Sletta, Geir Klinkenberg, Asgeir Winnberg · 2011 · Journal of Microbiological Methods
121. Oxaliplatin in Colon Cancer
     Mario Mandalà, Gianluigi Ferretti, Sandro Barni · 2004 · New England Journal of Medicine
122. BAK, BAX and p53 proteins in the apoptotic response to cisplatin
     Aleksandra Mandic, Kristina Viktorsson, Mark Varsanyi · 2001 · Nature Genetics